PTX-TCO

The incorporation of TCO into the paclitaxel molecule provides a way to direct the delivery of the drug to tumor sites. When the TCO is reacted with a Diels-Alder partner, such as a tetrazine, at the site of a tumor, paclitaxel can be released in a controlled manner. This targeting helps to minimize the exposure of non-cancerous tissues to the drug, reducing side effects.

The bioorthogonal nature of the TCO moiety allows for the possibility of using imaging agents in conjunction with paclitaxel-TCO conjugates. This dual functionality can enable real-time tracking of drug distribution and bioavailability within the body, helping clinicians monitor the efficacy of chemotherapy treatments.

msds of PTX-TCO